Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Breast cancer, metastatic

2770 - PERNETTA – A non comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207)


21 Oct 2018


Poster Discussion session - Breast cancer, metastatic


Cytotoxic Therapy

Tumour Site

Breast Cancer


Jens Huober


Annals of Oncology (2018) 29 (suppl_8): viii90-viii121. 10.1093/annonc/mdy272


J. Huober1, P. Weder2, C. Veyret3, B. Thürlimann2, A. Xyrafas4, L. Vanlemmens5, S. Guiu6, E. Brain7, J. Grenier8, F. Dalenc9, C. Levy10, A.M. Savoye11, A. Müller12, V. Membrez-Antonioli13, M.A. Gerard14, J. Lemonnier15, H. Hawle16, E. Boven17, H. Bonnefoi18

Author affiliations

  • 1 Breast Center, University hospital Ulm, 89075 - Ulm/DE
  • 2 Breast Center, Cantonal hospital St. Gallen, 9007 - St. Gallen/CH
  • 3 Medical Oncology, Centre Henri Becquerel, 76038 - Rouen/FR
  • 4 Statistics, SAKK - Swiss Group for Clinical Cancer Research, 3008 - Bern/CH
  • 5 Medical Oncology, Centre Oscar Lambret, 59020 - Lille/FR
  • 6 Medical Oncology, Reginal cancer institute, 34298 - Montpellier/FR
  • 7 Department Of Medical Oncology, Institut Curie, 75005 - Paris & Saint-Cloud/FR
  • 8 Medical Oncology, Institut Ste Catherine, 84082 - Avignon/FR
  • 9 Medical Oncology, Centre Claudius-Regaud, 31052 - Toulouse/FR
  • 10 Medical Oncology, Centre Francois Baclesse, 14076 - Caen/FR
  • 11 Medical Oncology, Institut Jean Godinot, 51056 - Reims/FR
  • 12 Department Of Medical Oncology, Kantonsspital Winterthur, Winterthur/CH
  • 13 Medical Oncology, Hospital of Valais, 1951 - Sion/CH
  • 14 Clinical research Center, SAKK - Swiss Group for Clinical Cancer Research, 3008 - Bern/CH
  • 15 R&d, Unicancer, 75654 - Paris/FR
  • 16 Clinical research, SAKK - Swiss Group for Clinical Cancer Research, 3008 - Bern/CH
  • 17 Medical Oncology, Vrije University Medical Centre (VUMC), 1081 HV - Amsterdam/NL
  • 18 Medical Oncology, Institute Bergonié, 33076 - Bordeaux/FR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2770


Dual blockade with P plus T is highly active as 1st-line treatment in patients (pts) with HER2+ MBC. In 2nd line therapy T-DM1 is considered standard of care. We hypothesize that a strategy with dual blockade with T+P without chemotherapy followed by T-DM1 at progression could be less toxic with similar efficacy in terms of overall survival (OS).


Pts with centrally confirmed HER2+ MBC were randomized 1:1 to receive either P+T alone (arm A) or P+T combined with weekly paclitaxel or vinorelbine (arm B), followed by maintenance treatment with T+P until progression. After progression, T-DM1 was given as second line therapy in both arms. The primary endpoint was OS at 24 months (mo), described by the proportion of successes, along with the exact Clopper-Pearson confidence interval (CI). Secondary endpoints included progression free survival (PFS) and time to failure of strategy (TFS: PD after having received both 1st and 2nd-line treatment or death to any reason).


Between 05/13 and 01/16, 210 pts were enrolled. Median age was 58 years, 63% of pts had lung or liver metastases, 36% of tumors were hormone receptor negative, paclitaxel / vinorelbine was given in 46/59 pts. In both arms, 2-year OS was the same. 61/44 of pts of arm A/B proceeded to 2nd line treatment with T-DM1. There were more hematologic, gastrointestinal, neurological toxicities and more alopecia in arm B. Efficacy results.Table: 288PD

Kaplan-Meier estimatorsP+TP+T with chemo
[%/median (95% CI)][%/median (95% CI)]
2-year OS (%)*76.2 (68.4-82.9)*76.2 (68.4-82.9)*
3-year OS (%)73.0 (62.8-80.8)73.1 (62.3-81.2)
1st line PFS (median - mo)#8.4 (7.7-12.0)23.3 (17.6-32.6)
2nd line PFS (T-DM1, median - mo)7.0 (4.3-11.3)5.3 (4.0-10.3)
TFS (median - mo)33.6 (23.2-not reached)48.6 (39.5-not reached)

Binomial with 90% CI reported;


1st CNS metastasis was ignored for this endpoint.


P+T alone as first line treatment followed by T-DM1 is a reasonable therapeutic strategy in HER2+MBC. Despite shorter PFS and TFS survival at 2 and 3 years was not affected and side effects were less frequently seen in the chemotherapy free arm. T-DM1 as second line therapy is active and safe after dual blockade with T+P.

Clinical trial identification

EudraCT: 2012-002556-17.

Legal entity responsible for the study

Sakk-Swiss Group for Clinical Cancer Research.



Editorial Acknowledgement


J. Huober: Travel grants, advisory board: Novartis, Roche, Pfizer, Celgene. P. Weder: Consultant, advisory board: MSD, Roche. B. Thürlimann: Stock ownership (Roche) and advisory board (Roche). E. Brain: Honoraria or consultation fees (Roche). All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.